{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T20:08:36Z","timestamp":1776888516554,"version":"3.51.2"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2024,11,8]],"date-time":"2024-11-08T00:00:00Z","timestamp":1731024000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,11,8]],"date-time":"2024-11-08T00:00:00Z","timestamp":1731024000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100006447","name":"University of Zurich","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100006447","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Heart Fail Rev"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>In recent years, sodium-glucose co-transporter 2 inhibitors (SGLT2i) emerged as promising therapeutic agents in managing heart failure (HF). They demonstrated a significant impact on reducing HF hospitalizations and related mortality in patients with reduced and preserved ejection fraction. However, evidence supporting their use in patients with left ventricular assist device (LVAD) and heart transplant (HT) recipients is still limited. We identified six key studies investigating the safety and efficacy of SGLT2i in LVAD and HT recipients. In patients with LVAD, prescription of SGLT2i was predominantly associated with improved fluid management and reduced pulmonary artery pressures. However, the results regarding their effects on body weight, hemoglobin A1c, diuretic use, and right ventricular function were contradictory. In terms of safety, SGLT2i were generally well-tolerated in the LVAD population, and the reported incidence of adverse events was low. In HT recipients, SGLT2i were associated with better glycemic control and weight reduction. No relevant adverse events were reported. Despite these encouraging results, the long-term safety and efficacy of SGLT2i in these vulnerable patient populations are yet to be investigated. Future randomized controlled trials are needed to address existing gaps in evidence and help integrate SGLT2i into clinical practice for LVAD and HT recipients.<\/jats:p>\n          <jats:p>\n            <jats:bold>Graphical abstract<\/jats:bold>\n          <\/jats:p>","DOI":"10.1007\/s10741-024-10465-z","type":"journal-article","created":{"date-parts":[[2024,11,8]],"date-time":"2024-11-08T14:04:29Z","timestamp":1731074669000},"page":"327-335","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Sodium-glucose co-transporter 2 inhibitors in left ventricular assist device and heart transplant recipients: a mini-review"],"prefix":"10.1007","volume":"30","author":[{"given":"Emyal","family":"Alyaydin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dana\u00eb","family":"Parianos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julia","family":"Hermes-Laufer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthias P.","family":"N\u00e4gele","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liesa","family":"Castro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Papathanasiou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Holger","family":"Reinecke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreas J.","family":"Flammer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,11,8]]},"reference":[{"key":"10465_CR1","doi-asserted-by":"publisher","unstructured":"McMurray JJV, Solomon SD, Inzucchi SE et al (2019) Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med 381(21):1995\u20132008. https:\/\/doi.org\/10.1056\/NEJMoa1911303","DOI":"10.1056\/NEJMoa1911303"},{"key":"10465_CR2","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","volume":"383","author":"M Packer","year":"2020","unstructured":"Packer M, Anker SD, Butler J et al (2020) Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med 383:1413\u20131424. https:\/\/doi.org\/10.1056\/NEJMoa2022190","journal-title":"N Engl J Med"},{"key":"10465_CR3","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","volume":"385","author":"SD Anker","year":"2021","unstructured":"Anker SD, Butler J, Filippatos G et al (2021) Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med 385:1451\u20131461. https:\/\/doi.org\/10.1056\/NEJMoa2107038","journal-title":"N Engl J Med"},{"key":"10465_CR4","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1056\/NEJMoa2206286","volume":"387","author":"SD Solomon","year":"2022","unstructured":"Solomon SD, McMurray JJV, Claggett B et al (2022) Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction. N Engl J Med 387:1089\u20131098. https:\/\/doi.org\/10.1056\/NEJMoa2206286","journal-title":"N Engl J Med"},{"key":"10465_CR5","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1161\/CIRCULATIONAHA.122.061732","volume":"146","author":"M Packer","year":"2022","unstructured":"Packer M (2022) Critical reanalysis of the mechanisms underlying the cardiorenal benefits of SGLT2 inhibitors and reaffirmation of the nutrient deprivation signaling\/autophagy hypothesis. Circulation 146:1383\u20131405. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.122.061732","journal-title":"Circulation"},{"key":"10465_CR6","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1186\/s12933-022-01506-8","volume":"21","author":"P Paolisso","year":"2022","unstructured":"Paolisso P, Bergamaschi L, Santulli G et al (2022) Infarct size, inflammatory burden, and admission hyperglycemia in diabetic patients with acute myocardial infarction treated with SGLT2-inhibitors: a multicenter international registry. Cardiovasc Diabetol 21:77. https:\/\/doi.org\/10.1186\/s12933-022-01506-8","journal-title":"Cardiovasc Diabetol"},{"key":"10465_CR7","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1111\/dom.14255","volume":"23","author":"J Oldgren","year":"2021","unstructured":"Oldgren J, Laurila S, \u00c5kerblom A et al (2021) Effects of 6 weeks of treatment with dapagliflozin, a sodium-glucose co-transporter-2 inhibitor, on myocardial function and metabolism in patients with type 2 diabetes: a randomized, placebo-controlled, exploratory study. Diabetes Obes Metabol 23:1505\u20131517. https:\/\/doi.org\/10.1111\/dom.14255","journal-title":"Diabetes Obes Metabol"},{"key":"10465_CR8","doi-asserted-by":"publisher","first-page":"800","DOI":"10.2337\/db20-0921","volume":"70","author":"KM Lauritsen","year":"2021","unstructured":"Lauritsen KM, Nielsen BRR, Tolbod LP et al (2021) SGLT2 inhibition does not affect myocardial fatty acid oxidation or uptake, but reduces myocardial glucose uptake and blood flow in individuals with type 2 diabetes: a randomized double-blind, placebo-controlled crossover trial. Diabetes 70:800\u2013808. https:\/\/doi.org\/10.2337\/db20-0921","journal-title":"Diabetes"},{"key":"10465_CR9","doi-asserted-by":"publisher","first-page":"2781","DOI":"10.2147\/DMSO.S258593","volume":"13","author":"T Nguyen","year":"2020","unstructured":"Nguyen T, Wen S, Gong M et al (2020) Dapagliflozin activates neurons in the central nervous system and regulates cardiovascular activity by inhibiting SGLT-2 in mice. Diabetes Metab Syndr Obes 13:2781\u20132799. https:\/\/doi.org\/10.2147\/DMSO.S258593","journal-title":"Diabetes Metab Syndr Obes"},{"key":"10465_CR10","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1016\/j.healun.2020.03.010","volume":"39","author":"RL Kormos","year":"2020","unstructured":"Kormos RL, Antonides CFJ, Goldstein DJ et al (2020) Updated definitions of adverse events for trials and registries of mechanical circulatory support: a consensus statement of the mechanical circulatory support academic research consortium. J Heart Lung Transpl 39:735\u2013750. https:\/\/doi.org\/10.1016\/j.healun.2020.03.010","journal-title":"J Heart Lung Transpl"},{"key":"10465_CR11","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.1056\/NEJMoa1800866","volume":"378","author":"MR Mehra","year":"2018","unstructured":"Mehra MR, Goldstein DJ, Uriel N et al (2018) Two-year outcomes with a magnetically levitated cardiac pump in heart failure. N Engl J Med 378:1386\u20131395. https:\/\/doi.org\/10.1056\/NEJMoa1800866","journal-title":"N Engl J Med"},{"key":"10465_CR12","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1016\/j.healun.2017.07.019","volume":"36","author":"LH Lund","year":"2017","unstructured":"Lund LH, Khush KK, Cherikh WS et al (2017) The registry of the International Society for Heart and Lung Transplantation: thirty-fourth adult heart transplantation report-2017; focus theme: allograft ischemic time. J Heart Lung Transpl 36:1037\u20131046. https:\/\/doi.org\/10.1016\/j.healun.2017.07.019","journal-title":"J Heart Lung Transpl"},{"key":"10465_CR13","doi-asserted-by":"publisher","unstructured":"Lumish HS, Singh S, Veldtman GR et al (2022) New-onset diabetes in patients post-heart transplantation: the role of hypertension and novel diabetic medications. J Heart Lung Transpl 41. https:\/\/doi.org\/10.1016\/j.healun.2022.01.800","DOI":"10.1016\/j.healun.2022.01.800"},{"issue":"2","key":"10465_CR14","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1002\/ejhf.886","volume":"20","author":"\u00c1 L\u00f3pez-Sainz","year":"2018","unstructured":"L\u00f3pez-Sainz \u00c1, Barge-Caballero E, Barge-Caballero G et al (2018) Late graft failure in heart transplant recipients: incidence, risk factors and clinical outcomes. Eur J Heart Fail 20(2):385\u2013394. https:\/\/doi.org\/10.1002\/ejhf.886","journal-title":"Eur J Heart Fail"},{"key":"10465_CR15","doi-asserted-by":"publisher","first-page":"100154","DOI":"10.1016\/j.ahjo.2022.100154","volume":"18","author":"M Cagliostro","year":"2022","unstructured":"Cagliostro M, Hundal P, Ting P et al (2022) Safety and effects of SGLT-2 inhibitor use among LVAD patients with type 2 diabetes mellitus. Am Heart J Plus 18:100154. https:\/\/doi.org\/10.1016\/j.ahjo.2022.100154","journal-title":"Am Heart J Plus"},{"key":"10465_CR16","doi-asserted-by":"publisher","first-page":"765","DOI":"10.2459\/JCM.0000000000001531","volume":"24","author":"G Moady","year":"2023","unstructured":"Moady G, Ben Avraham B, Aviv S et al (2023) The safety of sodium-glucose co-transporter 2 inhibitors in patients with left ventricular assist device: a single center experience. J Cardiovasc Med (Hagerstown) 24:765\u2013770. https:\/\/doi.org\/10.2459\/JCM.0000000000001531","journal-title":"J Cardiovasc Med (Hagerstown)"},{"key":"10465_CR17","doi-asserted-by":"publisher","first-page":"131259","DOI":"10.1016\/j.ijcard.2023.131259","volume":"391","author":"S Chavali","year":"2023","unstructured":"Chavali S, Barua S, Adji A et al (2023) Safety and tolerability of sodium-glucose cotransporter-2 inhibitors in bridge-to-transplant patients supported with centrifugal-flow left ventricular assist devices. Int J Cardiol 391:131259. https:\/\/doi.org\/10.1016\/j.ijcard.2023.131259","journal-title":"Int J Cardiol"},{"key":"10465_CR18","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1111\/aor.14733","volume":"48","author":"A Fardman","year":"2024","unstructured":"Fardman A, Kodesh A, Siegel AJ et al (2024) The safety of sodium glucose transporter 2 inhibitors and trends in clinical and hemodynamic parameters in patients with left ventricular assist devices. Artif Organs 48:902\u2013911. https:\/\/doi.org\/10.1111\/aor.14733","journal-title":"Artif Organs"},{"key":"10465_CR19","doi-asserted-by":"publisher","DOI":"10.1097\/TXD.0000000000000885","author":"MG Cehic","year":"2019","unstructured":"Cehic MG, Muir CA, Greenfield JR et al (2019) Efficacy and safety of empagliflozin in the management of diabetes mellitus in heart transplant recipients. Transpl Direct. https:\/\/doi.org\/10.1097\/TXD.0000000000000885","journal-title":"Transpl Direct"},{"key":"10465_CR20","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1016\/j.healun.2021.02.012","volume":"40","author":"Y Sammour","year":"2021","unstructured":"Sammour Y, Nassif M, Magwire M et al (2021) Effects of GLP-1 receptor agonists and SGLT-2 inhibitors in heart transplant patients with type 2 diabetes: initial report from a cardiometabolic center of excellence. J Heart Lung Transpl 40:426\u2013429. https:\/\/doi.org\/10.1016\/j.healun.2021.02.012","journal-title":"J Heart Lung Transpl"},{"key":"10465_CR21","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1186\/s13019-021-01589-6","volume":"16","author":"A Juraszek","year":"2021","unstructured":"Juraszek A, Sm\u00f3lski M, Ko\u0142sut P et al (2021) Prevalence and management of driveline infections in mechanical circulatory support: a single center analysis. J Cardiothorac Surg 16:216. https:\/\/doi.org\/10.1186\/s13019-021-01589-6","journal-title":"J Cardiothorac Surg"},{"key":"10465_CR22","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s13613-019-0490-2","volume":"9","author":"S Pons","year":"2019","unstructured":"Pons S, Sonneville R, Bouadma L et al (2019) Infectious complications following heart transplantation in the era of high-priority allocation and extracorporeal membrane oxygenation. Ann Intensive Care 9:17. https:\/\/doi.org\/10.1186\/s13613-019-0490-2","journal-title":"Ann Intensive Care"},{"key":"10465_CR23","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1016\/j.cardfail.2021.01.004","volume":"27","author":"G Gulati","year":"2021","unstructured":"Gulati G, Ruthazer R, Denofrio D et al (2021) Understanding longitudinal changes in pulmonary vascular resistance after left ventricular assist device implantation. J Card Fail 27:552\u2013559. https:\/\/doi.org\/10.1016\/j.cardfail.2021.01.004","journal-title":"J Card Fail"},{"key":"10465_CR24","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1016\/j.jtcvs.2006.10.060","volume":"133","author":"D Zimpfer","year":"2007","unstructured":"Zimpfer D, Zrunek P, Roethy W et al (2007) Left ventricular assist devices decrease fixed pulmonary hypertension in cardiac transplant candidates. J Thorac Cardiovasc Surg 133:689\u2013695. https:\/\/doi.org\/10.1016\/j.jtcvs.2006.10.060","journal-title":"J Thorac Cardiovasc Surg"},{"key":"10465_CR25","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1161\/CIRCULATIONAHA.120.052503","volume":"143","author":"ME Nassif","year":"2021","unstructured":"Nassif ME, Qintar M, Windsor SL et al (2021) Empagliflozin effects on pulmonary artery pressure in patients with heart failure: results from the EMBRACE-HF trial. Circulation 143:1673\u20131686. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.120.052503","journal-title":"Circulation"},{"key":"10465_CR26","doi-asserted-by":"publisher","DOI":"10.1002\/pul2.12028","author":"NE King","year":"2022","unstructured":"King NE, Brittain E (2022) Emerging therapies: the potential roles of SGLT2 inhibitors, GLP1 agonists, and ARNI therapy for ARNI pulmonary hypertension. Pulm Circ. https:\/\/doi.org\/10.1002\/pul2.12028","journal-title":"Pulm Circ"},{"key":"10465_CR27","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1161\/CIRCULATIONAHA.123.064346","volume":"148","author":"M Packer","year":"2023","unstructured":"Packer M, Wilcox CS, Testani JM (2023) Critical analysis of the effects of SGLT2 inhibitors on Renal Tubular Sodium, Water and Chloride Homeostasis and their role in Influencing Heart failure outcomes. Circulation 148:354\u2013372. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.123.064346","journal-title":"Circulation"},{"key":"10465_CR28","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1056\/NEJMoa2204233","volume":"388","author":"WG Herrington","year":"2023","unstructured":"The EMPA-KIDNEY Collaborative Group, Herrington WG, Staplin N et al (2023) Empagliflozin in patients with chronic kidney disease. N Engl J Med 388:117\u2013127. https:\/\/doi.org\/10.1056\/NEJMoa2204233","journal-title":"N Engl J Med"},{"key":"10465_CR29","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1016\/j.healun.2015.03.011","volume":"34","author":"K Takeda","year":"2015","unstructured":"Takeda K, Takayama H, Colombo PC et al (2015) Incidence and clinical significance of late right heart failure during continuous-flow left ventricular assist device support. J Heart Lung Transpl 34:1024\u20131032. https:\/\/doi.org\/10.1016\/j.healun.2015.03.011","journal-title":"J Heart Lung Transpl"},{"key":"10465_CR30","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.healun.2016.08.010","volume":"36","author":"JD Rich","year":"2017","unstructured":"Rich JD, Gosev I, Patel CB et al (2017) The incidence, risk factors, and outcomes associated with late right-sided heart failure in patients supported with an axial-flow left ventricular assist device. J Heart Lung Transpl 36:50\u201358. https:\/\/doi.org\/10.1016\/j.healun.2016.08.010","journal-title":"J Heart Lung Transpl"},{"key":"10465_CR31","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.2215\/CJN.02480221","volume":"16","author":"HJL Heerspink","year":"2021","unstructured":"Heerspink HJL, Cherney DZI (2021) Clinical implications of an acute dip in eGFR after SGLT2 inhibitor initiation. Clin J Am Soc Nephrol 16:1278\u20131280. https:\/\/doi.org\/10.2215\/CJN.02480221","journal-title":"Clin J Am Soc Nephrol"},{"issue":"6","key":"10465_CR32","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1161\/CIRCULATIONAHA.121.058910","volume":"146","author":"C Adamson","year":"2022","unstructured":"Adamson C, Docherty KF, Heerspink HJL et al (2022) Initial decline (dip) in estimated glomerular filtration rate after initiation of dapagliflozin in patients with heart failure and reduced ejection fraction: insights from DAPA-HF. Circulation 146(6):438\u2013449. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.121.058910","journal-title":"Circulation"},{"issue":"4","key":"10465_CR33","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1016\/j.kint.2020.10.042","volume":"99","author":"M Oshima","year":"2021","unstructured":"Oshima M, Jardine MJ, Agarwal R et al (2021) Insights from CREDENCE trial indicate an acute drop in estimated glomerular filtration rate during treatment with canagliflozin with implications for clinical practice. Kidney Int 99(4):999\u20131009. https:\/\/doi.org\/10.1016\/j.kint.2020.10.042","journal-title":"Kidney Int"},{"key":"10465_CR34","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1093\/aje\/kwx049","volume":"186","author":"A Mor","year":"2017","unstructured":"Mor A, Dekkers OM, Nielsen JS et al (2017) Impact of glycemic control on risk of infections in patients with type 2 diabetes: a Population-based Cohort Study. Am J Epidemiol 186:227\u2013236. https:\/\/doi.org\/10.1093\/aje\/kwx049","journal-title":"Am J Epidemiol"},{"key":"10465_CR35","doi-asserted-by":"publisher","first-page":"68","DOI":"10.20945\/2359-3997000000440","volume":"66","author":"LC Pinto","year":"2021","unstructured":"Pinto LC, Rados DV, Remonti LR et al (2021) Dose-ranging effects of SGLT2 inhibitors in patients with type 2 diabetes: a systematic review and meta-analysis. Arch Endocrinol Metab 66:68\u201376. https:\/\/doi.org\/10.20945\/2359-3997000000440","journal-title":"Arch Endocrinol Metab"},{"key":"10465_CR36","doi-asserted-by":"publisher","first-page":"2151","DOI":"10.1111\/dom.15091","volume":"25","author":"A Kang","year":"2023","unstructured":"Kang A, Smyth B, Neuen BL et al (2023) The sodium-glucose cotransporter-2 inhibitor canagliflozin does not increase risk of non-genital skin and soft tissue infections in people with type 2 diabetes mellitus: a pooled post hoc analysis from the CANVAS program and CREDENCE randomized double-blind trials. Diabetes Obes Metab 25:2151\u20132162. https:\/\/doi.org\/10.1111\/dom.15091","journal-title":"Diabetes Obes Metab"},{"key":"10465_CR37","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1161\/HYPERTENSIONAHA.118.11728","volume":"72","author":"MW Brands","year":"2018","unstructured":"Brands MW (2018) Role of insulin-mediated antinatriuresis in sodium homeostasis and hypertension. Hypertension 72:1255\u20131262. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.118.11728","journal-title":"Hypertension"}],"container-title":["Heart Failure Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10741-024-10465-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10741-024-10465-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10741-024-10465-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,6]],"date-time":"2025-02-06T07:58:26Z","timestamp":1738828706000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10741-024-10465-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,8]]},"references-count":37,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025,3]]}},"alternative-id":["10465"],"URL":"https:\/\/doi.org\/10.1007\/s10741-024-10465-z","relation":{},"ISSN":["1573-7322"],"issn-type":[{"value":"1573-7322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,8]]},"assertion":[{"value":"1 November 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 November 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"E. A. reports educational and training grant from the European Society of Cardiology (ESC), congress grants from the Heart Failure Association of the ESC, congress grants from the German Society of Cardiology and German Society of Internal Medicine, all unrelated to this article. M.P.N. reports speaker fees by AstraZeneca and Vifor Pharma unrelated to the article, consultancy fees by Boehringer Ingelheim and Pierre Fabre, and congress travel support by Pfizer, all unrelated to the article. H.R. reports personal fees from Daiichi Sankyo, Pfizer, MedUpdate, StreamedUp, DiaPlan, NeoVasc, Pluristem, NovoNordisk and Corvia. institutional grants from Pluristem, BMS, Pfizer, Bard and Biotronik. A.J.F. reports fees from Alnylam, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Fresenius, Medtronic, MSD, Mundipharma, Novartis, NovoNordisk, Pierre Fabre, Pfizer, Roche, Vifor, and Zoll, as well as grant support by Novartis, AstraZeneca and Berlin Heart unrelated to this article. All other authors declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}